首页> 外文OA文献 >139P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany

【2h】

139P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany

机译：139P在第2行或其他线疗法中对第3代TKI治疗的EGFR MT + NSCLC IV患者的TP53突变的影响：来自德国两次认证的肺癌中心的现实世界数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J. Roeper; P. Christopoulos; M. Falk; L.C. Heukamp; A. Stenzinger; M. Thomas; F. Griesinger;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts [J] . J. Roeper, M. Falk, S. Schatz, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P1.01-82在EGFR MT + PTS中没有接收第二线疗法的风险：EGFR MT + PTS治疗序列的认证肺癌中心的真实世界数据
2. P2.03b-022 Outcome in Molecularly Defined NSCLC within the NOWEL Network: The Influence of Sequential 2nd and 3rd Generation TKI in EGFR mt+ and ALK+ pts [J] . Julia Roeper, Maria Netchaeva, Anne Lueers, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.03b-022在NOTEL网络中分子定义的NSCLC中的结果：顺序第2和第3代TKI在EGFR MT +和ALK + PTS中的影响
3. P2.03b-022 Outcome in Molecularly Defined NSCLC within the NOWEL Network: The Influence of Sequential 2nd and 3rd Generation TKI in EGFR mt+ and ALK+ pts [J] . Julia Roeper, Maria Netchaeva, Anne Lueers, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.03b-022在NOTEL网络中分子定义的NSCLC中的结果：顺序第2和第3代TKI在EGFR MT +和ALK + PTS中的影响
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR PFS and OS in EGFR mt+ NSCLC [O] . Julia Roeper, Markus Falk, Athena Chalaris-Rißmann, 2020

机译：IV期EGFR突变患者中TP53共突变：EGFR mt + NSCLC中ORRPFS和OS的强预测因子
7. P2.03b-022 Outcome in Molecularly Defined NSCLC within the NOWEL Network: The Influence of Sequential 2nd and 3rd Generation TKI in EGFR mt+ and ALK+ pts [O] . Julia Roeper, Maria Netchaeva, Anne Lueers, 2017

机译：P2.03b-022在NOTEL网络中分子定义的NSCLC中的结果：顺序第2和第3代TKI在EGFR MT +和ALK + PTS中的影响

139P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany

著录项

引文网络

相似文献

相关主题

期刊订阅